Trials / Terminated
TerminatedNCT03127449
AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations
Multiple-Centered Study of AST2818 in Patients With Advanced Non-small Cell Lung Cancer With EGFR Mutations
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 116 (actual)
- Sponsor
- Allist Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is conducted to assess the safety, tolerability and preliminary efficacy of AST2818 in patients with advanced Non Small Cell Lung Cancer (NSCLC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Alflutinib | patients take Alflutinib orally once per day at different dose |
Timeline
- Start date
- 2017-06-01
- Primary completion
- 2021-05-12
- Completion
- 2024-01-08
- First posted
- 2017-04-25
- Last updated
- 2025-04-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03127449. Inclusion in this directory is not an endorsement.